- Home
- GNTX vs LEGN Comparison
GNTX vs LEGN Comparison
Compare GNTX & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNTX
- LEGN
- Stock Information
- Founded
- GNTX 1974
- LEGN 2014
- Country
- GNTX United States
- LEGN United States
- Employees
- GNTX N/A
- LEGN N/A
- Industry
- GNTX Auto Parts:O.E.M.
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- GNTX Consumer Discretionary
- LEGN Health Care
- Exchange
- GNTX Nasdaq
- LEGN Nasdaq
- Market Cap
- GNTX 4.8B
- LEGN 5.4B
- IPO Year
- GNTX N/A
- LEGN 2020
- Fundamental
- Price
- GNTX $23.44
- LEGN $44.03
- Analyst Decision
- GNTX Buy
- LEGN Strong Buy
- Analyst Count
- GNTX 7
- LEGN 11
- Target Price
- GNTX $27.93
- LEGN $74.60
- AVG Volume (30 Days)
- GNTX 2.3M
- LEGN 1.6M
- Earning Date
- GNTX 07-25-2025
- LEGN 08-08-2025
- Dividend Yield
- GNTX 2.05%
- LEGN N/A
- EPS Growth
- GNTX N/A
- LEGN N/A
- EPS
- GNTX 1.72
- LEGN N/A
- Revenue
- GNTX $2,299,862,212.00
- LEGN $728,303,000.00
- Revenue This Year
- GNTX $7.38
- LEGN $65.33
- Revenue Next Year
- GNTX $7.17
- LEGN $54.68
- P/E Ratio
- GNTX $13.63
- LEGN N/A
- Revenue Growth
- GNTX N/A
- LEGN 112.46
- 52 Week Low
- GNTX $20.28
- LEGN $27.34
- 52 Week High
- GNTX $33.57
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- GNTX 59.40
- LEGN 74.04
- Support Level
- GNTX $22.83
- LEGN $38.53
- Resistance Level
- GNTX $23.50
- LEGN $43.75
- Average True Range (ATR)
- GNTX 0.45
- LEGN 1.57
- MACD
- GNTX 0.01
- LEGN 0.38
- Stochastic Oscillator
- GNTX 64.21
- LEGN 87.82
About GNTX Gentex Corporation
Gentex was founded in 1974 to produce smoke-detection equipment. The company sold its first glare-control interior mirror in 1982 and its first model using electrochromic technology in 1987. Automotive revenue is about 98% of total revenue. The company is constantly developing new applications for the technology to remain on top. Sales in 2024 totaled about $2.3 billion with 47.7 million mirrors shipped. The unit mix breaks out as 63% interior and 37% exterior, versus 31% exterior in 2019. The company is based in Zeeland, Michigan.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.